<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022165</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068791</org_study_id>
    <secondary_id>SURREY-UK-PRECISE</secondary_id>
    <secondary_id>EU-20113</secondary_id>
    <nct_id>NCT00022165</nct_id>
  </id_info>
  <brief_title>Selenium in the Prevention of Cancer</brief_title>
  <official_title>Prevention Of Cancer By Intervention With Selenium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Surrey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Surrey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development of cancer. Selenium may be effective in preventing cancer. It is not yet known
      which dose of selenium may be most effective in preventing cancer.

      PURPOSE: Randomized pilot study to determine the effectiveness of selenium in preventing
      cancer in healthy people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether daily supplementation with selenium significantly reduces
      total cancer incidence and site-specific cancer incidence in the general population. II.
      Determine whether this regimen has a beneficial effect on mood.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.
      Participants are stratified according to age (60-64 vs 65-69 vs 70-74). Participants are
      randomized to one of four arms. Arm I: Participants receive oral placebo once daily. Arm II:
      Participants receive low-dose oral selenium once daily. Arm III: Participants receive
      moderate-dose oral selenium once daily. Arm IV: Participants receive high-dose oral selenium
      once daily. Treatment in all arms continues for up to 2 years in the absence of unacceptable
      side effects or diagnosis of cancer.

      PROJECTED ACCRUAL: A total of 510 patients (170 per stratum) will be accrued for this study
      within 9-12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">January 2002</completion_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Selenium yeast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium yeast 100 micrograms per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 micrograms per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium yeast 200 micrograms per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 micrograms per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium yeast 300 micrograms per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 micrograms per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>selenium</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Selenium yeast 100 micrograms per day</arm_group_label>
    <arm_group_label>Selenium yeast 200 micrograms per day</arm_group_label>
    <arm_group_label>Selenium yeast 300 micrograms per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Healthy men and women No prior diagnosis of cancer except
        non-melanoma skin cancer

        PATIENT CHARACTERISTICS: Age: 60 to 74 Performance status: SWOG 0-1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: No active liver disease No known abnormal
        liver function Renal: No active kidney disease No known abnormal kidney function Other: HIV
        negative No diminished mental capacity that would preclude study

        PRIOR CONCURRENT THERAPY: No other concurrent selenium supplements (50 ug/day or more)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Rayman, DPhil</last_name>
    <role>Study Chair</role>
    <affiliation>University of Surrey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Kingdom Coordinating Committee on Cancer Research-ABC</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Surrey</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 5XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>March 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2004</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

